Otsuka Pharmaceutical Reports Results from Two P-III Trials of Centanafadine to Treat ADHD
Shots:
- Both P-III clinical trials (NCT05257265) & (NCT05428033) evaluated the safety, efficacy & tolerability of Centanafadine (high/low dose) vs PBO in adolescents (aged 13-17yrs. & 6-12yrs.) with attention-deficit/hyperactivity disorder (ADHD) across the US & Canada
- The results from both trials depicted a change from baseline at 6wks. on the ADHD-RS-5 scale along with a statically significant improvement in high dose cohort vs PBO whereas the low-dose cohorts did not reach statistical significance
- Centanafadine, a norepinephrine, dopamine, and serotonin reuptake inhibitor, is currently under clinical studies following which the company plans to submit an NDA to the US FDA
Ref: Businesswire | Image: Otsuka
Related News:- Otsuka and Astex Receive EC’s Approval for Inaqovi (decitabine and cedazuridine) to Treat Newly Diagnosed Acute Myeloid Leukaemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
